Fewer than a tenth of patients who could benefit from obesity jabs like Wegovy are able to get them, states the WHO as it issues its initial advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging broader and more equitable availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be managed with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant barriers to universal availability to the injections that can aid individuals in losing significant weight, notes the body.
Skinny Jab Scarcity
Even in the present most favorable scenario, the production of these medications would only suffice for about 100 million people – under 10% of eligible patients, per the health organization.
The advice urges governments and firms to widen access, through measures such as voluntary licensing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Work
These medications replicate a body's own hormone to delay gastric emptying, suppress the appetite and enhance feelings of fullness so users reduce food intake.
Patients usually see weight reduction within a few weeks of commencing the weekly injections.
Studies suggests users may regain a significant portion a year later of halting the drug, as their typical food cravings resume.
Being carrying excess weight raises your chance for contracting diseases, including type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects individuals in every country and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
